Generic drug makers are applauding the latest change to the health care bill -- eliminating the ban on patent settlements. The measure, which was backed by the Federal Trade Commission, would in most cases have barred so-called "pay for delay" settlements of patent cases brought by generic companies against brand-name drug makers. In such cases, the brand-name maker pays the generic company to delay the market entry of a lower-cost generic drug alternative.
March 18, 2010 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Generic drug makers are applauding the latest change to the health care bill — eliminating the ban on patent settlements.
The measure, which was backed by the Federal Trade Commission, would in most cases have barred so-called “pay for delay” settlements of patent cases brought by generic companies against brand-name drug makers. In such cases, the brand-name maker pays the generic company to delay the market entry of a lower-cost generic drug alternative.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
